Official publication of Rawalpindi Medical University
Depression and anxiety in glaucoma patients using mono drug therapy vs polydrug therapy

Supplementary Files

PDF

How to Cite

1.
Tahir A, Ahmed MW, Khan S, Zafar O, Sarfraz MH, Tarar MS. Depression and anxiety in glaucoma patients using mono drug therapy vs polydrug therapy . JRMC [Internet]. 2023 Jun. 24 [cited 2023 Sep. 29];27(2). Available from: https://journalrmc.com/index.php/JRMC/article/view/1910

Abstract

Objective: To evaluate the frequency of depression, anxiety, and stress scores among glaucoma patients and assess factors attributing to severe scores.

Methodology: This Analytical, Cross-sectional study was conducted at the Armed Forces Institute of Ophthalmology from June 2020 to July 2021. Data was collected through nonprobability consecutive sampling. Individuals with diagnosed primary open-angle glaucoma were selected irrespective of age and gender. Dass-21 (self-assessment scale) was used in Urdu to document patient scores for anxiety, depression, and stress.

Results: The frequency of males (n=204, 54%) and females (n=173, 45.8%) in the two groups was almost the same (p=0.164). The mean age in the mono-drug group (mean= 48.81±10.58 years) was slightly lower than the polydrug group (mean=53.67±11.16years) (p=0.000018). Overall depression score of the sample fell in the severe category (score=21-27), with individuals showing more depression scores in the poly group (n=99, 26%) than in the mono drug group (n=76, 20%) (p=0.000002). Individuals on polydrug therapy showed severe scores for depression, anxiety, and stress.

Conclusion: Among the glaucoma patient, those on polydrug therapy have higher incidences of anxiety among young patients and depression among older patients. This not only causes poor compliance to treatment but also increases the risk of progression of glaucoma hence augmenting the crippling effects of the disease.

Keywords: Depression, anxiety, DASS-21, Glaucoma

https://doi.org/10.37939/jrmc.v27i2.1910

References

Bertaud S, Aragno V, Baudouin C, Labbé A. Le glaucome primitif à angle ouvert [Primary open-angle glaucoma]. Rev Med Interne. 2019 Jul;40(7):445-452. French. doi: 10.1016/j.revmed.2018.12.001.

Li H, Ge S, Greene B, Dunbar-Jacob J. Depression in the context of chronic diseases in the United States and China. Int J Nurs Sci. 2018 Nov 29;6(1):117-122. doi: 10.1016/j.ijnss.2018.11.007.

Sanchez FG, Mansberger SL, Newman-Casey PA. Predicting Adherence With the Glaucoma Treatment Compliance Assessment Tool. J Glaucoma. 2020 Nov;29(11):1017-1024. doi: 10.1097/IJG.0000000000001616

Robin AL, Muir KW. Medication adherence in patients with ocular hypertension or glaucoma. Expert Review of Ophthalmology. 2019 Sep 3;14(4-5):199-210. DOI: 10.1080/17469899.2019.1635456

Zhang X, Olson DJ, Le P, Lin FC, Fleischman D, Davis RM. The Association Between Glaucoma, Anxiety, and Depression in a Large Population. Am J Ophthalmol. 2017 Nov;183:37-41. doi: 10.1016/j.ajo.2017.07.021.

Gamiochipi-Arjona JE, Azses-Halabe Y, Tolosa-Tort P, Lazcano-Gómez G, Gonzalez-Salinas R, Turati-Acosta M, García-Huerta M, Jiménez-Román J. Depression and Medical Treatment Adherence in Mexican Patients With Glaucoma. J Glaucoma. 2021 Mar 1;30(3):251-256. doi: 10.1097/IJG.0000000000001739.

Shin DY, Jung KI, Park HYL, Park CK. The effect of anxiety and depression on the progression of glaucoma. Sci Rep. 2021 Jan 19;11(1):1769. doi 10.1038/s41598-021-81512-0.

Liu ML, Wang YX. [The prevalence of blindness caused by primary angle closure glaucoma in middle-aged Chinese population: a systematic review and meta-analysis]. Zhonghua Yan Ke Za Zhi. 2017 May 11;53(5):373-377. Chinese. doi: 10.3760/CMA.j.issn.0412-4081.2017.05.010.

Le MTH, Tran TD, Holton S, Nguyen HT, Wolfe R, Fisher J. Reliability, convergent validity and factor structure of the DASS-21 in a sample of Vietnamese adolescents. PLoS One. 2017 Jul 19;12(7):e0180557. doi 10.1371/journal.pone.0180557.

Rezapour J, Nickels S, Schuster AK, Michal M, Münzel T, Wild PS, Schmidtmann I, Lackner K, Schulz A, Pfeiffer N, Beutel ME. Prevalence of depression and anxiety among participants with glaucoma in a population-based cohort study: The Gutenberg Health Study. BMC Ophthalmol. 2018 Jun 28;18(1):157. doi: 10.1186/s12886-018-0831-1

Onwubiko SN, Nwachukwu NZ, Muomah RC, Okoloagu NM, Ngwegu OM, Nwachukwu DC. Factors associated with depression and anxiety among glaucoma patients in a tertiary hospital South-East Nigeria. Niger J Clin Pract. 2020 Mar;23(3):315-321. doi: 10.4103/njcp.njcp_140_19.

Abe RY, Silva LNP, Silva DM, Vasconcellos JPC, Costa VP. Prevalence of depressive and anxiety disorders in patients with glaucoma: a cross-sectional study. Arq Bras Oftalmol. 2021 Jan-Feb;84(1):31-36. doi: 10.5935/0004-2749.20210006.

Lim NC, Fan CH, Yong MK, Wong EP, Yip LW. Assessment of Depression, Anxiety, and Quality of Life in Singaporean Patients With Glaucoma. J Glaucoma. 2016 Jul;25(7):605-12. doi: 10.1097/IJG.0000000000000393.

Kausar A, Ali M, Masud H, Akhtar F. Vision-related quality of life in Pakistani subjects with early or moderate glaucoma. Int Health. 2018 Nov 1;10(6):517-523. doi: 10.1093/inthealth/ihy052.

Stamatiou ME, Kazantzis D, Theodossiadis P, Chatziralli I. Depression in glaucoma patients: A review of the literature. Semin Ophthalmol. 2022 Jan 2;37(1):29-35. doi: 10.1080/08820538.2021.1903945.

Chen YY, Lai YJ, Wang JP, Shen YC, Wang CY, Chen HH, Hu HY, Chou P. The association between glaucoma and risk of depression: a nationwide population-based cohort study. BMC Ophthalmol. 2018 Jun 22;18(1):146. doi: 10.1186/s12886-018-0811-5.

Vélez-Gómez MC, Vásquez-Trespalacios EM. Adherence to topical treatment of glaucoma, risk and protective factors: A review. Arch Soc Esp Oftalmol (Engl Ed). 2018 Feb;93(2):87-92. English, Spanish. doi: 10.1016/j.oftal.2017.07.012.

Skalicky SE, D'Mellow G, House P, Fenwick E; Glaucoma Australia Educational Impact Study Contributors. Glaucoma Australia educational impact study: a randomized short-term clinical trial evaluating the association between glaucoma education and patient knowledge, anxiety and treatment satisfaction. Clin Exp Ophthalmol. 2018 Apr;46(3):222-231. doi: 10.1111/ceo.13016. Epub 2017 Aug 11

Otori Y, Takahashi G, Urashima M, Kuwayama Y; Quality of Life Improvement Committee. Evaluating the Quality of Life of Glaucoma Patients Using the State-Trait Anxiety Inventory. J Glaucoma. 2017 Nov;26(11):1025-1029. doi: 10.1097/IJG.0000000000000761.

Meier-Gibbons F, Töteberg-Harms M. Influence of Cost of Care and Adherence in Glaucoma Management: An Update. J Ophthalmol. 2020 Apr 8;2020:5901537. doi: 10.1155/2020/5901537

Shin DY, Jung KI, Park HYL, Park CK. The effect of anxiety and depression on progression of glaucoma. Sci Rep. 2021 Jan 19;11(1):1769. doi: 10.1038/s41598-021-81512-0.

Sabel BA, Wang J, Cárdenas-Morales L, Faiq M, Heim C. Mental stress as consequence and cause of vision loss: the dawn of psychosomatic ophthalmology for preventive and personalized medicine. EPMA J. 2018 May 9;9(2):133-160. doi: 10.1007/s13167-018-0136-8

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Copyright (c) 2023 Aaiza Tahir